Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs glucocorticoid immunosuppressants in adult minimal change nephropathy
ChiCTR2100054244Phase 4Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in nephrosis (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: 12-month urine protein complete remission and partial remission rate. Started Jan 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on ChiCTR2100054244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054244.